Gate Neurosciences to Present New Synaptic Function Molecule Research at 2024 ASCP Annual Meeting

A clinical-stage biotechnology company focused on precision medicine to develop next-generation neuroscience therapies announced its upcoming activities at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami Beach, FL, from May 28-31, 2024. The company will present new preclinical and clinical data supporting its NMDAR PAM portfolio and share novel insights from internal research on the biological mechanisms of neuroplasticity and synaptic function.

Gate Neurosciences will highlight its cutting-edge research on how a single dose of neuroplasticity-enhancing drugs can trigger both rapid-onset (i.e., hours) and long-lasting therapeutic effects (i.e., weeks), a phenomenon termed ‘event-driven pharmacology.’ New insights have been gained into CNS-specific ‘event-driven pharmacology’ and the importance of dosing intervals to optimize plasticity treatments.

These new findings will be shared at the company’s 3rd Annual R&D Day during the conference, with leading members of the scientific community in attendance. The session will also include updates on an upcoming Phase 2 study with a once-weekly oral program, zelquistinel (GATE-251), for Major Depressive Disorder.

Gate Neurosciences 3rd Annual R&D Day at ASCP 2024:

  • Location: Loews Hotel Miami Beach, Florida
  • Date: Tuesday, May 28, 2024
  • Time: 12:15 p.m. to 1:45 p.m.

“Over the past few years, the Gate team has made considerable progress in understanding mechanisms that rapidly and durably enhance synaptic function for treating CNS diseases. Dosing these compounds the right way is critical to success,” stated Mike McCully, CEO of Gate Neurosciences. “We look forward to sharing our new data and insights with the psychiatry community at the ASCP conference and discussing updated plans for our Phase 2 study of once-weekly oral zelquistinel in depression.”

Poster Presentation Details:

  • Poster #T14
    • Title: Apimostinel, a Novel NMDAR Modulator with Rapid-Acting, Sustained Effects and Favorable Drug-Like Properties: Preclinical Studies
    • Abstract Number: T14
    • Presentation Session: Poster Session II, Salon 4
    • Presentation Date and Time: 12:30 p.m. – 2:25 p.m., Thursday, May 30, 2024
    • Lead Author: Jeffrey Burgdorf, PhD

Key takeaways from Poster #T14 include:

  • A single dose of apimostinel acutely enhanced LTP with metaplasticity lasting 7 days and produced robust antidepressant-like effects without ketamine-like side effects.
  • Apimostinel dose-dependently enhanced qEEG alpha in correlation with CSF exposure as a biomarker of NMDA receptor target activation.
  • Repeat doses of apimostinel led to larger and longer-lasting metaplastic effects.
  • Poster #T21
    • Title: A Phase 1 Safety, Pharmacokinetics (PK) and Quantitative Electroencephalography (qEEG) Pharmacodynamics Study of Single and Multiple Ascending Doses of Intravenous Apimostinel Compared with Placebo in Healthy Volunteers
    • Abstract Number: T21
    • Presentation Session: Poster Session II, Salon 4
    • Presentation Date and Time: 12:30 p.m. – 2:25 p.m., Thursday, May 30, 2024
    • Lead Author: Ronald M. Burch, MD, PhD

Key takeaways from Poster #T21 include:

  • Apimostinel was generally safe and well-tolerated following multiple doses from 1-25mg.
  • Apimostinel dose-dependently stimulated qEEG alpha power.
  • qEEG alpha power stimulation with apimostinel was consistent with CSF Cmax drug concentrations that maximally stimulate NMDA receptors in vitro.
  • qEEG alpha power stimulation with apimostinel was consistent with efficacious doses in a previous Phase 2a clinical MDD study.

Full abstracts will be published by ASCP following the conclusion of the 2024 Annual Meeting.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter